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1. Introduction 
Recent advances in the development of therapeutic strategies have enabled the cure of a 
considerable amount of cases of breast cancer patients. However, breast cancer is a worldwide 
problem since this disease remains a common cause of cancer death in women throughout the 
world (Álvarez 2010). Although breast cancer can be regulated by chemotherapy, there are still 
difficulties with treating recurrence and triple-negative breast cancer without therapeutic 
molecular targets (HER2 and hormone receptors) (Foulkes et al. 2010). Therefore, it is 
necessary to increase the knowledge of breast cancer biology and investigate target molecules 
to facilitate therapeutic strategy toward aggressive breast cancers. 
Hypercoagulation is a common complication of cancer patients and also correlates with 
mortality (Ten Cate & Falanga 2007). In fact, it has been reported that the risk of venous 
thromboembolism (VTE) is highest for cancers of the ovary, pancreas, liver (Iodice et al., 
2008), and breast during chemotherapy (Kirwan et al. 2008). 
Blood coagulation factor VII (fVII) is a key enzyme of the extrinsic coagulation cascade that 
is produced predominantly by hepatocytes (Furie & Furie 1988). Tissue factor (TF) is a 47-
kD transmembrane glycoprotein and a cellular receptor of fVII. Blood coagulation factor VII 
from blood plasma bound to TF is converted to its active form (fVIIa) and activates a 
downstream extrinsic coagulation cascade, leading to fibrin deposition (Fig. 1).  
It has been reported that plasma TF levels are higher in cancer patients including advanced 
breast cancer (Ueno et al. 2000). Furthermore, breast cancer cells secrete cell membrane-
derived microvesicles containing TF antigen under pathological conditions, resulting in 
coagulation activation (Davila et al. 2008). Therefore, TF-fVIIa formation can be a major 
cause of thromboembolic disease. 
A number of studies have demonstrated that tissue factor-fVIIa complex formation on the cell 
surface also initiates key pathogenic events including activation of cell motility, invasiveness, 
cell survival, and angiogenesis (Milsom & Rak 2009). Recently, growing experimental 
evidence has also suggested that TF contributes to tumor initiation (Milsom & Rak 2009). 
Given that fVII presents on the invasive edge of various cancer tissues (Fischer et al. 1999;  
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Fig. 1. Extrinsic coagulation cascade initiated by TF-fVIIa complex formation. 
TF-fVIIa complex formation on the cell surface triggers an extrinsic coagulation cascade. TF-
fVIIa initiates coagulation by activating factor X, resulting in fibrin deposition via formation 
of thrombin. The mechanism of mediation via factor IX activation is also possible. 
Zacharski et al. 1993), this suggests that TF-fVIIa complex formation may play a critical role 
in malignant phenotype expression of clinical tumors. Therefore, anti-TF strategy may be 
applicable to breast cancer although a probable side effect of bleeding should be considered. 
Blood plasma has been considered to be a predominant source of fVII present on cancer cell 
surfaces since most plasma proteins including fVII are produced in the liver. Blood 
coagulation factor VII is believed to penetrate through hyperpermeabilized blood vessels 
around tumor tissues (McDonald & Baluk 2002), and then associate with the integral 
membrane protein TF of cancer cells. However, various cancer cells can ectopically 
synthesize fVII (Koizume et al. 2006). Notably, breast cancer cells were found to 
constitutively and highly express fVII mRNA by RT-PCR analysis. Further, functional fVII 
exists as a complex with TF on the cell surface (Koizume et al. 2006). Unsurprisingly, fVII 
mRNA expression is frequently found in surgical specimens of breast cancer (Koizume et al. 
2009), suggesting that fVII is synthesized in cancer tissues of patients and that ectopic fVII 
synthesis may play an important role in the biology of breast cancer. Therefore, inhibition of 
ectopic fVII synthesis without affecting fVII secreted from the liver may be a useful 
therapeutic approach for breast cancer patients. In this chapter, recent progress in breast 
cancer biology associated with TF-fVIIa signaling and in the biology of ectopic synthesis of 
fVII in breast cancer cells will be summarized. In addition to descriptions based on 
previously published data, new data mainly concerning cell growth accelerating 
characteristics of ectopic fVII in breast cancer cells will be presented. Finally, potential future 
therapeutic strategies of breast cancer targeting ectopic fVII will be discussed. Recently a 
target molecule specifically associated with the ectopically active FVII gene promoter but 
not with the FVII promoter in hepatocytes (Koizume et al. 2009) was found. Therefore, 
ectopic fVII synthesis can be selectively blocked without disturbing the normal haemostatic 
process. 
2. Biology of TF-fVIIa signaling in breast cancer cells 
Considerable progress has been made towards understanding of how cancer cells depend on 
TF-fVIIa complex formation to express their malignant phenotypes (Milsom & Rak 2009; 
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Mackman & Taubman 2009; Schaffner & Ruf 2009). To date, a number of studies concerning 
TF-fVIIa signaling have been performed using breast cancer cell lines such as MDA-MB-231, 
MCF-7, and BT549, possibly because they express relatively high levels of TF, and their 
phenotypes such as motility and invasiveness are TF-dependent (Jiang et al. 2008; Morris et al. 
2006). Among these cell lines, MDA-MB-231 synthesizes a considerable amount of TF and is a 
frequently used cell line as a good TF-dependent breast cancer model. Its characteristics such 
as motility, invasiveness, and growth are highly TF-dependent in response to fVII in vitro 
(Hjortoe et al. 2004; Jiang et al. 2004; Morris et al. 2006) and in vivo (Versteeg et al. 2008a & b). 
TF-fVIIa signaling mechanisms potentially resulting in breast cancer phenotypes can be 
classified into three categories. The first is signaling mediated by TF-fVIIa binary complex 
formation. Various experimental evidence has suggested that activation of a G protein-
coupled receptor, protease activated receptor 2 (PAR2) rather than PAR1 by the TF-fVIIa 
complex plays a crucial role in phenotypic expression of breast cancer cells through 
activation of the mitogen-activated protein kinase cascade (Hjortoe et al. 2004; Morris et al. 
2006; Versteeg et al. 2008a). Second, TF-fVIIa signaling could involve coagulation factor X 
(fX) to transmit signals. The TF-fVIIa complex may further interact with fX to produce the 
TF-fVIIa-fXa ternary complex (Jiang et al. 2004). Breast cancer phenotypes mediated via TF-
fVIIa-fXa complex formation may not only cause PAR2 signaling but also activate PAR1 to 
initiate thrombin signaling. This ternary complex may also activate the mTOR pathway in 
breast cancer cells (Jiang et al. 2008). Third, the G protein–independent pathway of PAR2 
signaling is also possible in breast cancer cells (Schaffner et al. 2010). PAR2 recruits a 
scaffold protein, -arrestin, to support extracellular signal-regulated kinase signaling to 
enhance cell motility. In any case, TF-fVIIa signaling may eventually enhance expression of 
downstream effectors, such as IL-8 (Hjortoe et al. 2004), Cyr61 (Pendurthi et al. 2000), CTGF 
(Pendurthi et al. 2000), VEGF (Liu & Mueller 2006), CXCL1 (Albrektsen et al. 2007; Versteeg 
et al. 2008b), Birc3 (Albrektsen et al. 2007), CUX1 (Wilson et al. 2009), and CSF (Albrektsen et 
al. 2007), which then contribute to malignant phenotype expression of breast cancers. 
While phenotypes regulated by TF-fVIIa formation seem dependent on PAR2 signaling, breast 
cancer cells could augment invasiveness and tumorigenesis by PAR1 signaling (Booden et al. 
2004). PAR1 is a thrombin receptor that is highly expressed in invasive breast cancer cells. 
Treatment of breast cancer cells with thrombin increases cellular invasion in a PAR1-
dependent manner. On the other hand, PAR1 can be a receptor of matrix metalloprotease-1 
secreted from stromal cells and it enhances invasiveness and tumorigenesis of MDA-MB-231 
cells (Boire et al. 2005). Therefore, it is likely that the relative importance of PAR1 and PAR2 
signaling in breast cancer progression is dependent on the tumor microenvironment.  
Characteristics of breast cancer cells might be influenced by exogenous TF in patients. 
Recent in vitro experiments revealed that growth and metastatic properties of breast cancer 
cells can also be affected by TF in a paracrine manner (Collier et al. 2008). Treatment with 
recombinant TF mimicking stroma-derived TF enables breast cancer cells to be more 
invasive and proliferative via activation of 1-integrins and/or PAR2 signaling cascades, 
followed by down-regulation of estrogen receptor gene expression.  
3. Expression of TF in breast cancer tissues 
3.1 Expression of TF activity in breast cancer tissues 
Immunohistochemical analyses have revealed that breast cancer tissues as well as ovarian 
and pancreatic cancer tissues highly express TF (Contrino et al. 1996; Ueno et al. 2000). 
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Although the mechanisms of this overexpression have not been clearly defined, 
transcriptional up-regulation appears to be a major cause of this aberrant expression. 
Mechanisms of transcriptional regulation of the TF gene (F3) have been well characterized 
(Mackman 1995). Basal F3 gene expression is known to be regulated by various transcription 
factors such as Sp1, AP-1, and NFB. Given that AP-1 and NFB are major factors activated 
in breast cancer (Benz & Yau 2008), it is likely that aberrant activation of these factors is 
associated with higher TF levels. Indeed, it has been reported that the F3 gene promoter is 
highly occupied by these transcription factors in MDA-MB-231 cells, whereas the promoter 
is weakly bound in TF low-expressing MCF-7 cells (Zhou et al. 1998).  
Inducible expression of the F3 gene is another plausible cause of high TF expression in 
cancer tissues. Expression of TF is known to be affected by various environmental stimuli 
such as exposure to cytokines, growth factors, and hypoxia (Milsom & Rak 2009), leading to 
activation of AP-1 and NFB. Therefore, expression levels of TF can be varied depending on 
the tumor microenvironment. Besides environmental factors, expression of TF is also 
affected by oncogenic events such as activation of ras, p53, PTEN, and EGFR (Milsom & Rak 
2009). Expression of the F3 gene can be up-regulated through signaling cascade downstream 
of these effectors. 
The transcription factor Egr-1 is also known to play a major role in inducible TF expression 
(Mackman 1995). Briefly, Sp1 mainly contributes to basal up-regulation of F3 transcription. 
However, once cells are stimulated with various factors associated with the cellular 
microenvironment, expression of Egr-1 is induced in cancer cells. Since Egr-1 shares DNA 
binding sites with Sp1, it could thus substitute Sp1 binding within the promoter region to 
enhance TF transcription under pathological conditions. 
Post transcriptional regulation may also determine TF expression or activity level in breast 
cancer cells. A major mechanism is inhibition by tissue factor pathway inhibitor (TFPI), 
directly inhibiting serine protease activity of TF-fVIIa (Milsom & Rak 2009). Indeed, it was 
recently reported that breast cancer tissues highly express TFPI (Sierko et al. 2010). In 
addition, TFPI may augment cell adhesion (Fischer et al. 1999) and invasiveness (Sierko et 
al. 2010) through interaction with the TF-fVIIa complex. Another post-transcriptional 
mechanism is functional modification by conformational change. Procoagulant activity of TF 
can be regulated by conformational change called encryption/decryption, possibly 
mediated via multiple mechanisms (Bach 2006). However, recent studies using MDA-MB-
231 cell suggested that de-encryption of TF is caused via interaction with anionic 
phospholipids rather than intra-molecular disulfide exchange (Pendurthi et al. 2007). Only 
decrypted TF can exert its procoagulant activity, while encrypted TF still has the ability to 
transmit signals. It was recently found that a microRNA (miR-19) could bind to 3’-UTR of 
the TF transcript to repress translation in breast cancer cells (Zhang et al. 2010). This study 
showed that miR-19 is abundant in a TF low-expressing breast cancer cell line, MCF-7, 
suggesting that regulation by this microRNA may be a determinant of TF levels in breast 
cancer tissues. 
In addition to cell surface expression, breast cancer cells can secrete TF as microparticles 
derived from cell membrane fragments in response to various stimuli in vitro and in vivo 
(Tilley et al. 2008; Davila et al. 2008); therefore, this circulating TF may increase the risk of 
thrombosis in patients. Further, besides expression in tumor parenchyma cells, tumor 
stroma produces TF to promote breast cancer metastasis (Vrana et al. 1996). Growth factors 
secreted from breast cancer cells may stimulate stromal cells to produce TF, resulting in 
breast cancer progression. 
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3.2 Relationship between TF expression and clinical outcome of breast cancer 
patients 
Activation of platelets (Kirwan et al. 2008) and elevation of plasma TF levels (Davila et al. 
2008) are candidate determinants for the development of thrombosis in cancer patients. 
Indeed, VTE post chemotherapy is relatively frequent for breast cancer patients, and 
therefore, the relationship between haemostatic markers and thrombosis was investigated 
(Kirwan et al. 2008). This study showed that plasma TF levels of patients were significantly 
higher than those of non-cancer controls, but they were not elevated in response to 
chemotherapy, suggesting that chemotherapy-induced VTE is due to TF-independent 
mechanisms. 
On the other hand, analysis with clinical samples revealed that TF is highly expressed in 
breast cancer patients. It has been reported that TF is expressed in vascular endothelial cells 
in invasive breast cancer tissues, suggesting that TF may be a marker for angiogenic 
phenotypes of breast cancer (Contrino et al. 1996). As well as tissue expression including 
stromal, vascular endothelial, and monocytic expression, TF levels are elevated in plasma of 
breast cancer patients. Although it was found that there was no difference in plasma TF 
levels between normal and benign tumors, primary and recurrent cancer patients showed 
significantly higher TF levels (Ueno et al. 2000). These expression patterns of TF are 
correlated with those in tissue samples. These TF levels are associated with tumor grade and 
can be an independent prognostic indicator. Further, TF levels in urine of breast cancer 
patients also correlate with disease malignancy (Lwaleed et al. 1999), suggesting that 
measurement of TF expression has some clinical advantages. 
Although molecular mechanisms linking TF levels and cancer phenotypes can be explained 
by multiple cellular events downstream of TF-fVIIa signaling pathways, recent 
immunohistochemical analyses have revealed that phosphorylation of the cytoplasmic 
domain of TF correlates with expression levels of TF and other proteins known to be 
associated with recurrence and aggressive phenotypes of breast cancers (Rydén et al. 2010). 
This study showed that TF phosphorylation associated with PAR2 expression correlates 
with recurrence in breast cancer patients. A recent in vivo study by the same group showed 
that the cytoplasmic domain of TF cooperates with PAR2 to promote breast cancer 
development through modulating the angiogenic response (Schaffner et al. 2010), providing 
a rationale for the observed clinical association. 
4. Ectopic expression of coagulation factor VII in breast cancer cells 
Although the major source of fVII is the liver under normal conditions, various cancer cells 
could ectopically synthesize fVII (Koizume et al. 2006). Notably, breast cancer cell lines, such 
as YMB-1, MDA-MB-453, and MCF-7, constitutively and highly express fVII mRNA as 
shown by RT-PCR analysis (Koizume et al. 2006). Recently, we additionally found by real-
time RT-PCR analysis that a breast cancer cell line, T47D, highly expresses fVII, and its 
mRNA level is comparable with that of YMB-1 (data not shown). Cancer cells that express 
fVII exhibit fXa-generating activity depending on TF-fVIIa complex formation, suggesting 
that ectopically synthesized fVII is functional and may play an important role in the 
progression of breast cancer. As mentioned above, fVII expression is frequent in surgical 
specimens of breast cancer by RT-PCR and immunohistochemical analyses (Koizume et al. 
2009). 
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4.1 Mechanism of constitutive fVII synthesis in breast cancer cells 
Transcript levels of fVII are higher in breast cancer cells, and therefore, it was examined 
whether the FVII gene is activated in breast cancer cells. It is known that binding of a 
transcription factor, HNF-4 is crucial for FVII gene activation in hepatocytes. However, 
HNF-4 is not responsible for FVII expression in breast cancer cells as shown by 
immunoblotting and chromatin immunoprecipitation (ChIP) analyses (Koizume et al. 2009). 
Reporter gene analysis showed that the authentic FVII promoter region could fully activate 
reporter activity in breast cancer cells. As expected, deletion of the HNF-4 binding site from 
the FVII promoter construct showed that reporter activity is not significantly impaired, 
further supporting the idea that HNF-4 is dispensable for ectopic FVII expression. Further, 
analysis with a reporter construct without a Sp1 transcription factor binding site showed a 
marked decrease in promoter activity in breast cancer cells (Koizume et al. 2009). These 
results indicate that Sp1 binding to the promoter region is essential for constitutive FVII 
activation in breast cancer cells. 
Histone acetylation within the gene promoter region is a crucial step for transcriptional 
activation, and therefore, epigenetic factors responsible for ectopic FVII expression were 
further explored (Koizume et al. 2009). Histone acetyltransferases (HATs) associated with 
the FVII promoter in breast cancer cells were examined. ChIP analysis revealed that major 
HATs, p300 and CBP are associated with the FVII promoter region in breast cancer cells. On 
the other hand, other HATs, PCAF and SRC-1, can also interact with the hepatocytic FVII 
promoter. Notably, the FVII promoter in HepG2 cells is devoid of p300 and CBP. ChIP 
analysis showed that histone H4 is hyperacetylated within the active FVII promoter in 
various cells, suggesting that p300 and CBP may be responsible for histone acetylation 
within the FVII promoter region in breast cancer cells, although various HATs can 
contribute to the acetylation in hepatocytes. 
fVII production in hepatocellular carcinoma and breast cancer cells was detected by western 
blotting and colorimetric analysis (Koizume et al. 2009). Unlike hepatocytes, fVII synthesized 
in YMB-1 cells is not secreted into culture media, suggesting that ectopically synthesized fVII 
is involved in TF-fVIIa complex formation on the cell surface in an autocrine manner. 
4.2 Induction of fVII expression in breast cancer cells under hypoxic conditions 
FVII transcription is inducible under hypoxia and hypoxia mimetic (CoCl2 treatment) 
conditions depending on the cell type (Koizume et al. 2006). To date, several cell lines have 
been found to express the fVII transcript in response to hypoxia. As ovarian cancer cells 
tend to express fVII in response to hypoxia (Koizume et al. 2006; Yokota et al. 2009), it was 
next tested whether breast cancer cell lines inducibly express fVII mRNA under hypoxic 
conditions. It was revealed that cell lines with high fVII expression, such as YMB-1 and 
MDA-MB-453, do not enhance fVII transcript levels in response to hypoxic stimuli 
(Koizume et al. 2009). However, we recently found that fVII mRNA is inducible in MDA-
MB-468 cells under CoCl2 treatment conditions (Fig. 2A), suggesting that induction of fVII in 
breast cancer cells is cell-type dependent. 
Detailed mechanisms of this hypoxic induction have not been defined yet. However, it is likely 
that a hypoxia inducible factor, HIF-2 may contribute to the activation. Chromatin 
immunoprecipitation analysis revealed that although both HIF-1 and HIF-2 are inducible 
under hypoxia-mimetic conditions (Fig. 2B), HIF-2 predominantly binds to the FVII promoter 
region in MDA-MB-468 cells (Fig. 2C), as in the case of OVSAYO cells (Koizume et al. 2006).  
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Fig. 2. Induction of the fVII transcript in MDA-MB-468 cells.  
(A) FVII activation in MDA-MB-468 cells treated with CoCl2. Cells were cultured for 4 hours 
in the presence or absence of 500 M CoCl2, and then fVII mRNA levels were analyzed by 
real-time RT-PCR analysis. Columns, mean (n = 2); bars, SD. (B) Western blotting analysis of 
HIF expression in MDA-MB-468 cells cultured with or without 500 M CoCl2 for 4 hours. 
(C) Chromatin immunoprecipitation (ChIP) analysis of HIFs binding to the FVII promoter in 
MDA-MB-468 cells. Cells were cultured in the presence or absence of 500 M CoCl2 for 4 
hours, and then subjected to ChIP analysis. I indicates input sonicated DNA fragments 
without immunoprecipitation. 
Notably, unlike typical transcriptional activation mechanisms by HIFs (Majmundar et al. 
2010), the promoter region bound by HIF-2 is devoid of the hypoxia responsible element 
(Koizume et al. 2006), and therefore, novel mechanisms of transcriptional regulation may 
contribute to FVII activation under hypoxia. 
5. Ectopically expressed fVII can enhance proliferation of breast cancer cells 
As in the case of exogenous fVII treatment of cancer cells, ectopically expressed fVII 
augments motility and invasiveness of breast cancer cells, MDA-MB-453, as well as ovarian 
cancer cells, OVSAYO (Koizume et al. 2006). Growth and development of some breast 
tumors are dependent on TF-fVIIa formation, followed by activation of PAR2 signaling 
(Versteeg et al. 2008a & b). This is characteristic of in vivo conditions since TF expression 
does not contribute to cell growth in monolayer culture (Yu et al. 2005; Versteeg et al. 
2008a). These results may simply be due to the absence of fVII in culture media and/or 
reflect the importance of host components of the tumor microenvironment (Jessani et al. 
2004). Therefore, we tested whether proliferation of breast cancer cells in vitro is affected by 
ectopic fVII synthesis. The cell lines YMB-1 and MDA-MB-453 were selected for this purpose 
since these cells highly express fVII mRNA (Koizume et al. 2006). 
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Fig. 3. Blood coagulation factor VII contributes to cell proliferation of MDA-MB-453 cells. 
(A) Knockdown of fVII expressed in YMB-1 and MDA-MB-453 cells. Cells were transfected 
with negative control- or fVII-siRNA. After 43 hours of transfection, whole cell lysates were 
analyzed by immunoblotting. (B) fXa generation analysis of breast cancer cells transfected 
with siRNA of fVII. Forty-three hours post transfection, cells were examined for fXa 
generation activity. Columns, mean (n = 3); bars, SD. *P < 0.05 (two-sided Student’s t test). (C, 
D) Cell proliferation analysis of fVII-expressing (YMB-1 and MDA-MB-453) and non-
expressing (MDA-MB-231) breast cancer cells after transfection of negative control- or fVII-
siRNA. Columns, mean (n = 3); bars, SD. *P < 0.05 (two-sided Student’s t test). 
Expression of fVII in YMB-1 and MDA-MB-453 cells is suppressed by small interference 
RNA (siRNA) transfection, resulting in reduction of protein levels (Fig. 3A) and cell surface 
procoagulant activity (Fig. 3B). After 24 hours post transfection, monitoring of cell growth 
was obtained by colorimetric assay. Growth of MDA-MB-453 cells was considerably 
diminished by fVII suppression (Fig. 3C and D). On the other hand, proliferation of YMB-1 
cells was not affected after 3 days post transfection (Fig. 3D). As expected, proliferation of 
MDA-MB-231 cells without fVII expression was not affected by siRNA transfection (Fig. 
3D), suggesting that fVII can enhance breast cancer cell proliferation, but the effect is cell-
type dependent. Western blotting of hormone receptors (Koizume et al. 2009) and 
fluorescent in situ hybridization analysis of ERBB2 amplification showed that YMB-1 cells 
correspond to the “triple negative” molecular subtype, although MDA-MB-453 cells are 
HER-2 positive (data not shown). 
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To test whether triple-negative breast cancer cells are unresponsive to ectopically 
synthesized fVII to activate cell proliferation, we next tested the effect of forced fVII 
expression on proliferation of other triple-negative breast cancer cells. 
 
 
Fig. 4. Effect of fVII overexpression on proliferation of MDA-MB-231 cells. 
(A) Procoagulant activity of fVII in MDA-MB-231 cells transfected with fVII. Cloned cells 
(231VII1 and 231 VII4) constitutively overexpressing fVII were transfected with negative 
control- or fVII-siRNA and then, examined for fXa generation activity. Columns, mean  
(n = 2); bars, SD. (B) Cell proliferation analysis of fVII-expressing cells with different 
procoagulant activity shown in (A). Columns, mean (n = 3); bars, SD. (C) Effect of fVII 
suppression on cell proliferation of 231VII1 cells. After 24 hours of fVII- or negative control- 
siRNA transfection, cells were examined for proliferation activity. Columns, mean (n = 3); 
bars, SD. (D) Effect of fVII suppression on cell proliferation of 231VII4 cells. After 24 hours of 
fVII- or negative control- siRNA transfection, cells were examined for proliferation activity. 
Columns, mean (n = 3); bars, SD. 
MDA-MB-231 cell was used for experiments since this cell line without fVII expression 
highly expresses TF and its growth in vivo is dependent on TF-fVIIa signaling (Versteeg et 
al. 2008a & b). Cell clones stably expressing fVII were prepared and fVII expression levels 
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were analyzed by western blotting (data not shown) and fXa generation assay (Fig. 4A). 
Two cell clones with variation in fVII expression levels (Fig. 4A) were selected. Cell 
proliferation assay with these cells showed that the higher fVII is expressed, the faster breast 
cancer cells proliferate (Fig. 4B). Suppression of fVII synthesis by RNAi restored cell 
proliferation efficiency (Fig. 4C & D), while it did not affect proliferation of parental MDA-
MB-231 cells (Fig. 3D). These results show that ectopically expressed fVII can accelerate 
proliferation of triple-negative breast cancer cells. 
6. Strategy to inhibit ectopic fVII synthesis in breast cancer cells 
6.1 Inhibition of ectopic fVII synthesis in breast cancer cells by curcumin 
The expression of fVII may contribute to breast cancer metastasis and growth. Therefore, 
targeting fVII expression may be therapeutically beneficial if ectopic fVII could be 
specifically inhibited without precluding function of fVII secreted from the liver. We 
showed that the ectopically activated FVII promoter is associated with p300 and CBP, while 
the FVII promoter in hepatocytes can be bound by various HATs, suggesting that targeting 
p300 and CBP activities may fulfil selective inhibition (Koizume et al. 2009). To date, 
curcumin, a component of spice turmeric, is the only known compound to selectively block 
p300/CBP HAT activity. Therefore, the effect of this small compound on ectopic FVII 
expression in breast cancer cells was tested (Koizume et al. 2009). The breast cancer cells 
YMB-1 and MDA-MB-453 were cultured in the presence of curcumin, and then fVII mRNA 
levels were analyzed by real-time RT-PCR analysis. It was found that curcumin markedly 
reduced fVII transcript levels in these cells in a dose-dependent manner, while normal 
expression of FVII in hepatic cells was only weakly impaired (Koizume et al. 2009). 
Additionally, TF mRNA was not significantly diminished by the same curcumin 
concentrations in these cells. Furthermore, anacardic acid, another natural small compound 
inhibitor for p300 and PCAF, did not selectively inhibit ectopic FVII expression, suggesting 
that curcumin targets p300/CBP activity (Koizume et al. 2009). The effect of curcumin on 
FVII expression was further examined at the protein level and it was confirmed that 
curcumin selectively inhibits ectopic fVII synthesis, consistent with the results of mRNA 
analysis. However, HAT activity associated with the FVII promoter in hepatocytes including 
p300 and CBP is heterogeneous. Furthermore, we showed selective blockade of ectopic fVII 
synthesis using a limited number of cell lines; therefore it is possible that hepatocytic fVII 
synthesis can be considerably impaired by curcumin if p300/CBP is a major coactivator of 
the FVII gene. 
We tested whether curcumin treatment inhibits proliferation of fVII-expressing breast 
cancer cells. YMB-1 and MDA-MB-453 cells were cultured in the presence of curcumin as 
in the case of transcript analysis, and then cell proliferation was evaluated. As in the case 
of siRNA experiments, it was found that growth of YMB-1 was not reduced (data not 
shown) but proliferation of MDA-MB-453 cells was significantly impaired (~50% 
inhibition after 3 days post curcumin addition). We further tested whether the pro-
proliferation effect of ectopic fVII is dependent on TF-fVIIa formation on the cell surface. 
MDA-MB-453 cells were then cultured with anti-TF (5G9 or 10H10) antibody or negative 
control IgG. Cell proliferation after antibody addition was analyzed by colorimetric assay. 
We found that treatment of cells with these antibodies did not affect cell proliferation  
(Fig. 5A). 
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Fig. 5. Effect of TF-fVIIa formation on proliferation of breast cancer cells. 
(A) Cell proliferation analysis of MDA-MB-453 cells treated with anti-TF antibodies. Cells 
had 50 g/ml of IgG, Mab-5G9, or Mab-10H10 added, and then viable cells were monitored 
by colorimetric assay. Columns, mean (n = 3); bars, SD. (B) fXa generation analysis of MDA-
MB-231 cells treated with fVIIa. After 1 hour post addition of 10nM fVIIa, cells were 
washed twice and then fXa-generating activity due to TF-fVIIa formation on the cell surface 
was examined by colorimetric assay. Columns, mean (n = 2); bars, SD. (C) Cells were cultured 
with or without 20nM fVIIa. After 2 hours post fVIIa addition, cell proliferation was 
estimated by colorimetric assay. Columns, mean (n = 3); bars, SD. 
The same results were obtained by cell proliferation experiments (data not shown) with 
anti-PAR1 and –PAR2 antibodies (Koizume et al. 2006). We further tested the effect of TF-
fVIIa protease activity on cell proliferation by adding fVIIa to cell culture media. We 
confirmed that MDA-MB-231 cells pre-treated with fVIIa strongly generate pro-coagulant 
activity (Fig. 5B), but cell proliferation was not affected in the presence of fVIIa (Fig. 5C). 
These data indicate that mechanisms independent of TF-fVIIa formation on the cell surface 
may be involved in acceleration of cell proliferation driven by ectopic fVII synthesis. 
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6.2 Other effects of curcumin may augment anti-breast cancer efficacy of ectopic fVII 
repression 
Curcumin has been widely studied because this compound exhibits various anti-cancer 
effects such as pro-apoptotic, anti-angiogenic, and anti-metastatic activities (Sa & Das 2008). 
Therefore, anti-ectopic fVII activity in combination with other effects of curcumin may 
cooperate to suppress malignant phenotype expression of breast cancers. Many 
investigators have reported that curcumin has pro-apoptotic activity in cancer cells. The 
molecular mechanism of this effect can be attributed to repression of transcription factors 
crucial for cell survival. Curcumin can inhibit binding of Egr-1, NFB, and AP-1 to target 
genes in vitro (Bierhaus et al. 1997; Pendurthi et al. 1997), resulting in down-regulation of 
proteins essential for tolerance to cell death. Indeed, pro-apoptotic effects of curcumin have 
also been observed in vivo using mouse xenograft breast tumor models (Adams et al. 2004; 
Shoji et al. 2008). A chemosensitizing effect of curcumin via inhibition of the above 
transcription factors (Goel & Aggarwal 2010) or by targeting proteasomes (Landis-Piwowar 
et al. 2006; Zhang et al. 2007) has also been reported. Therefore, anti-cancer activity of 
curcumin can be a result of complex cellular events induced by inhibition of multiple target 
molecules. In addition, induction of TF expression under cellular stress can be suppressed 
by curcumin since the F3 gene is a target of Egr-1, NFB, and AP-1 for regulation (Bierhaus 
et al. 1997; Pendruthi et al. 1997). This indicates that curcumin can block a pathologically 
increased fraction of TF without impairing normal TF expression responsible for extrinsic 
hemostasis. Since anti-TF strategy may be therapeutically beneficial (Schaffner & Ruf 2009), 
use of curcumin may be advantageous since this compound could synergistically block 
malignant phenotypes caused by TF-ectopic fVIIa signaling without causing bleeding. 
7. Future directions 
Many breast cancer cell lines constitutively and highly express fVII (Fig. 6). Given that TF-
fVIIa signaling can be a major mechanism of malignant phenotype expression of breast 
cancers through enhancement of metastasis, angiogenesis, and anti-apoptotic effects, breast 
cancer cells possibly synthesize fVII as an optional means to survive in a severe tumor 
microenvironment unique to mammary tissue. In addition, ectopic fVII can promote cell 
proliferation. Since transcript and immunohistochemical analyses of clinical samples 
showed that breast cancer tissues frequently express fVII, anti-breast cancer strategies 
targeting ectopic fVII should be considered. 
It was found that curcumin selectively inhibits ectopic fVII synthesis by precluding 
p300/CBP binding to the FVII promoter region. Since animal studies have shown that 
curcumin can cure cardiovascular diseases by targeting p300 activity (Morimoto et al. 2008; 
Li et al. 2008), anti-p300 strategy by curcumin treatment is clinically applicable without 
significant toxicity. Therefore, for the next step, it will be necessary to examine whether an 
anti-p300/CBP strategy against fVII-expressing breast cancer is also effective in vivo. In 
addition, an anti-p300/CBP strategy may be compromised since HATs can be targeted to 
the hepatocytic FVII promoter. It is therefore necessary to discover novel molecular targets 
more specifically associated with ectopic fVII synthesis. Furthermore, although we showed 
that blockade of ectopic fVII synthesis by RNAi or curcumin treatment could repress cell 
proliferation, this inhibitory effect is cell-type dependent. Therefore, mechanistic 
understanding of this difference is also required to predict breast cancer cells responsive to 
an anti-ectopic fVII strategy. 
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Fig. 6. Breast cancer phenotypes potentially augmented by ectopic fVII expression. 
Blood coagulation factor VII can be synthesized via transcription from the FVII gene 
constitutively activated by activators such as Sp1 in breast cancer cells. Hypoxic stress may 
enhance this transcription via activation of the FVII promoter by binding of the transcription 
factor HIF-2. Ectopic fVII activity may be strengthened since expression of its cellular 
receptor, TF, can also be increased via F3 gene activation via Sp1 substitution by Egr-1 under 
pathological conditions such as hypoxia. Red symbols are indicative of events expected to 
occur under hypoxia. Bent arrows are indicative of transcriptional activation. Dotted arrows 
designate protein expression. 
From the clinical point of view, it is essential to reveal relationships between fVII expression 
and various clinical parameters, such as chemoresistance, relapse, and overall survival to 
predict patients who may benefit from anti-TF-fVIIa treatment. Notably, breast cancer 
prognosis is known to closely correlate with pathological complete response after adjuvant 
chemotherapy (Ross et al. 2008). Therefore, it is worth investigating whether chemoresistant 
patients express high levels of fVII as a survival factor so that fVII can be targeted to 
improve prognosis. 
Finally, many questions concerning the biology of ectopic fVII synthesis remain 
unanswered. Why do breast cancer cells tend to synthesize more fVII compared with other 
cancer cells? How does ectopically expressed fVII associate with TF to express TF-fVIIa 
complex on the cell surface? It would also be intriguing to investigate whether ectopically 
expressed fVII has novel functions other than authentic TF-fVIIa signaling. Notably, ectopic 
fVII might have a cytoplasmic function since we found that ectopic fVII accelerates breast 
cancer cell proliferation, possibly via a cell surface TF-fVIIa-independent mechanism. More 
specifically, does cytoplasmic fVII exist without complexing with TF to play a biological 
role? A more detailed understanding of how ectopic fVII expression is regulated and how it 
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can contribute to breast cancer biology will be essential for translating current knowledge to 
therapeutic strategies. 
8. Materials and methods 
8.1 Cell lines and reagents 
Human cancer cell lines, antibodies, and curcumin were as previously described (Koizume 
et al. 2009). fVIIa was kindly provided by Wolfram Ruf (Scripps Research Institute, La Jolla, 
CA). MDA-MB-231 cell lines constitutively expressing fVII were primarily prepared as 
previously described (Koizume et al. 2006). Briefly, the parent cell line was transfected with 
pIRES/fVII expression vector, and then clones resistant to puromycin exposure were 
isolated by passaging. The expression activity of fVII of cloned cells was primarily 
confirmed by fXa generation assay (Koizume et al. 2006). 
8.2 Chromatin immunoprecipitation, real-time PCR, and fXa generation analysis 
These experiments were performed as previously described (Koizume et al., 2006). 
8.3 RNAi experiments 
Small interference RNA (siRNA) for fVII was ON-TARGET plus SMART pool (Dharmacon, 
Lafayette, CA). Silencer Negative Control 1 RNAi (Ambion, Austin, TX) was used for non-
specific siRNA transfection. Transfection of siRNA was performed using the Neon™ 
transfection system (Invitrogen, Carlsbad, CA). 
8.4 Cell proliferation assay 
Cell proliferation was analyzed using CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay (Promega, Madison, WI). 
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